Allied Market Research

Pneumococcal Polysaccharide Vaccine Market 2023


Portland, OR -- (SBWIRE) -- 09/19/2017 -- Pneumococcal disease is an infection caused by the Streptococcus pneumoniae bacteria, which especially affects infants and children below 5 years of age. Pneumococcal polysaccharide vaccine is derived from a capsular polysaccharide. These vaccinations induce specific antibodies, which kills the bacteria by opsonization or phagocytosis.

The major factors that contribute to the growth of the Pneumococcal Polysaccharide Vaccine Market include increasing prevalence of pneumonia globally, improving healthcare infrastructure, rise in government focus on immunization programs for pneumonia, and development of quality vaccines such as PPSV23. However, high costs associated with the development of such vaccines and longer timelines required for pneumonia vaccine production hamper the growth of the global pneumococcal polysaccharide vaccine market. Growing awareness about pneumococcal vaccine and large numbers of mergers & acquisition strategies among key vendors are expected to propel the growth of the market in the near future.

Get PDF Brochure of this report:

The key players that operate in this market include Merck & Co., Inc., Pfizer Inc., Glaxosmithkline Plc., Sanofi Pasteur, China National Biotec Group, Astellas Pharma Inc, and Serum Institute of India Pvt. Ltd.

Pneumococcal Polysaccharide Vaccine Market Key Segments:

By Dosage

-Single Dose Vial
-Pre-Filled Syringe

By End User

-Children (2-10 Age)
-Adult (10-64 Age)
-Geriatric (More Than 65 Age)

Early buyers will receive 20% customization on this report